Literature DB >> 15241569

Blood flow alterations in TNBS-induced colitis: role of endothelin receptors.

M Deniz1, S Cetinel, H Kurtel.   

Abstract

OBJECTIVES: The aim of the present study was to investigate the time dependent changes in hemodynamic parameters and to assess the role of endothelin (ET) receptors in trinitrobenzene sulfonic acid (TNBS) induced colitis. MATERIALS: Inferior mesenteric artery (IMA) hemodynamics, myeloperoxidase activity (MPO) and damage scores were measured immediately or 1, 3, 5 and 14 days after colitis. TREATMENTS: Another group of rats received a nonselective ET receptor antagonist bosentan (30 mg/kg/day), ET-A receptor antagonist BQ485 (60 microg/rat/day) or ET-B receptor antagonist BQ788 (60 microg/rat/day) prior to and on the 1st, 2nd and 3rd days after TNBS administration.
RESULTS: IMA flow significantly increased at 90 min followed by a substantial decrease through days 1-5. Tissue MPO activity and macroscopic damage score increased on 1st day after the induction of colitis and remained elevated 3, 5 and 14 days following colitis. Treatment with bosentan or ET-A receptor antagonist largely prevented the colitis-induced reduction in blood flow and tissue injury whereas ET-B receptor antagonist did not attenuate tissue injury or reductions in blood flow.
CONCLUSIONS: Our results demonstrate that time-dependent abnormalities occur in IMA hemodynamics following TNBS administration. Our findings also indicate that ET-A receptors but not ET-B receptors play an important role in the colonic inflammation following TNBS administration.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15241569     DOI: 10.1007/s00011-004-1266-0

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  8 in total

1.  Isolation and Characterization of Putative Probiotic Bacterial Strain, Bacillus amyloliquefaciens, from North East Himalayan Soil Based on In Vitro and In Vivo Functional Properties.

Authors:  V I Hairul Islam; N Prakash Babu; P Pandikumar; S Ignacimuthu
Journal:  Probiotics Antimicrob Proteins       Date:  2011-12       Impact factor: 4.609

2.  Potential role for ET-2 acting through ETA receptors in experimental colitis in mice.

Authors:  R F Claudino; D F Leite; A F Bento; J G Chichorro; J B Calixto; G A Rae
Journal:  Inflamm Res       Date:  2016-10-24       Impact factor: 4.575

3.  Endothelin-1 receptor antagonist (LU-135252) improves the microcirculation and course of TNBS colitis in rats.

Authors:  Martin Kruschewski; Tanja Anderson; Christoph Loddenkemper; Heinz J Buhr
Journal:  Dig Dis Sci       Date:  2006-07-26       Impact factor: 3.199

4.  Endothelin and vascular remodelling in colitis pathogenesis--appendicitis and appendectomy limit colitis by suppressing endothelin pathways.

Authors:  Rajkumar Cheluvappa; Rajaraman Eri; Annie S Luo; Michael C Grimm
Journal:  Int J Colorectal Dis       Date:  2014-08-02       Impact factor: 2.571

5.  Effects of the endothelin-converting enzyme inhibitor SM-19712 in a mouse model of dextran sodium sulfate-induced colitis.

Authors:  Seungjun Lee; Patsy R Carter; Megan N Watts; Jianxiong R Bao; Norman R Harris
Journal:  Inflamm Bowel Dis       Date:  2009-07       Impact factor: 5.325

6.  The effects of resveratrol, a phytoalexin derived from red wines, on chronic inflammation induced in an experimentally induced colitis model.

Authors:  Antonio Ramón Martín; Isabel Villegas; Marina Sánchez-Hidalgo; Catalina Alarcón de la Lastra
Journal:  Br J Pharmacol       Date:  2006-04       Impact factor: 8.739

7.  The effect of Hypericum perforatum (St. John's Wort) on experimental colitis in rat.

Authors:  Turhan Dost; Hakan Ozkayran; Filiz Gokalp; Cigdem Yenisey; Mustafa Birincioglu
Journal:  Dig Dis Sci       Date:  2008-08-27       Impact factor: 3.199

8.  AT1R blocker losartan attenuates intestinal epithelial cell apoptosis in a mouse model of Crohn's disease.

Authors:  Tian-Jing Liu; Yong-Yan Shi; En-Bo Wang; Tong Zhu; Qun Zhao
Journal:  Mol Med Rep       Date:  2015-12-14       Impact factor: 2.952

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.